Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05089851 · ClinicalTrials.gov registry record · NA
Investigation of the Efficacy and Tolerability of a Cosmetic Product With Onabotulinumtoxin A in the Treatment of Facial Lines
A NA study, sponsored by Revision Skincare.
- Completed
- Registry status
- NA
- Development phase
- 29
- Enrollment target
NCT05089851 is a NA study that has completed, run by Revision Skincare. The registered enrollment target is 29 participants.
The verdict
NCT05089851, a NA study, has completed, sponsored by Revision Skincare.
- COMPLETED
- Registry status
- NA
- Development phase
- 29 participants
- Enrollment target
Study Summary
This randomized, multi-center, double-blinded, placebo-controlled, split-face clinical trial was conducted to evaluate the procedure-pairing of OnabotulinumtoxinA with a peptide anti-aging serum to improve facial lines and wrinkles, as well as overall skin texture and radiance of the face after 12 weeks of twice-daily use in female subjects ages 35 - 60 as compared to placebo. A total of 29 subjects completed study participation.
Interventions
- COMBINATION_PRODUCT Sunscreen
- PROCEDURE Onabotulinumtoxin A
- COMBINATION_PRODUCT Facial Cleanser
- COMBINATION_PRODUCT Facial Moisturizer
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2020-08-23 |
| Est. Completion | 2021-06-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05089851
The ClinicalTrials.gov registry entry for NCT05089851 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Revision Skincare, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Sunscreen is the first listed.
NCT05089851 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05089851 about?
NCT05089851 is a clinical study titled "Investigation of the Efficacy and Tolerability of a Cosmetic Product With Onabotulinumtoxin A in the Treatment of Facial Lines". This randomized, multi-center, double-blinded, placebo-controlled, split-face clinical trial was conducted to evaluate the procedure-pairing of OnabotulinumtoxinA with a peptide anti-aging serum to improve facial lines and wrinkles, as well as overall skin texture and radiance of the face after 12 w...
What is the current status of trial NCT05089851?
This trial is currently completed. It is a NA study. The enrollment target is 29 participants. The study started on 2020-08-23. Estimated completion is 2021-06-03.
What interventions are being tested in trial NCT05089851?
The interventions under investigation include: Sunscreen (COMBINATION_PRODUCT), Onabotulinumtoxin A (PROCEDURE), Facial Cleanser (COMBINATION_PRODUCT), Facial Moisturizer (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05089851?
This trial is sponsored by Revision Skincare, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.